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Abstract
Objective
To evaluate whether different quality assessment tools applied to a group of clinical
trials could be correlated, and what would be their impact on meta-analysis results.
Methods
Thirty-eight randomized controlled clinical trials were analyzed. These had been selected
for a systematic review of the therapeutic efficacy of alpha interferon for treating
chronic hepatitis B. The following tools were utilized: Maastricht (M), Delphi (D),
Jadad (J) and the Cochrane Collaboration (CC) method (gold standard). The Spearman
correlation coefficient was used to compare the results from the three methods. The
Kappa test was used to assess the concordance between the reviewers in applying the
tools, and the weighted Kappa test was applied to compare the quality ranking
determined by the tools. The outcomes assessed in the meta-analyses were clearance
of HBV-DNA and HBeAg.
Results
The studies presented regular to low quality. The concordance between reviewers
varied according to the instrument utilized: D=0.12; J=0.29; M=0.33; and CC=0.53.
The correlation was moderate and homogeneous (D/J=0.51; D/M=0.53; and J/
M=0.52). The meta-analysis result relating to HBV-DNA ranged from RR=0.71
(95% CI: 0.66-0.77) to RR=0.67 (95% CI: 0.58-0.79). For HBeAg, the results
ranged from RR=0.85 (95% CI: 0.80-0.90) to RR=0.85 ( 95% CI: 0.77-0.93). These
results depended on the quality of the studies included.
Conclusions
The quality assessment tools presented good correlation. In systematic reviews with
the same direction of effect, the quality assessment may not significantly change the
results. The Cochrane Collaboration method was the most reproducible method and
easiest to apply.
INTRODUCTION
The adoption of the paradigm of scientific ground-
ing for medical practice took place slowly and gradu-
ally over the course of the twentieth century, with an
acceleration towards the end of the century. This gave
rise to increasing quantities of articles published in
the medical literature. To enable such information to
be progressively assimilated, there was intensive pro-
duction of reviews, so-called narratives, grounded in
this concentrated experience.13
This process was dependent on the authors’ subjec-
tivity in relation to selecting and interpreting the in-
formation on related clinical topics, from both pub-
lished and unpublished data.15 In most cases, no ex-
plicit criteria for critically analyzing the information
were utilized. This meant that the conclusions and sug-
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assessment tools to clinical trials included in a sys-
tematic review on the efficacy of alpha interferon in
the treatment of chronic hepatitis B.
METHODS
An observational and analytical study was carried
out within the context of a systematic review on the
efficacy of treating chronic hepatitis B using alpha
interferon. Search strategies with different sensitivi-
ties and specificities were utilized, as suggested by
the liver and bile duct research group of the Cochrane
Collaboration, including all the clinical trials identi-
fied in the MedLine, EmBase and Lilacs databases
and in the Library of the Cochrane Collaboration.
The period covered was from 1966 to 2001.
The relevant clinical trials were identified in all
the databanks cited, by using the specific terms hepa-
titis B and Interferon and the following strategy: ran-
domized controlled trial [publication Type] OR con-
trolled clinical trial [Publication Type] OR rand-
omized controlled trial [Mesh Terms] OR random al-
location [Mesh Terms] OR double blind methods
[Mesh Terms] or single blind methods [Mesh Terms].
In all, 2,838 trials were identified, of which 46 were
randomized controlled clinical trials. From these, the
trials that referred only to comparisons between dif-
ferent doses of alpha interferon were removed (eight
studies). Thus, 38 clinical trials were selected.
Four distinct assessment methods for clinical trials
were utilized: the Maastricht, Delphi, Jadad and
Cochrane Collaboration methods.
Two pairs of reviewers took part in the study, who
worked independently. The Cochrane Collaboration
method was applied by two infectologists with train-
ing in clinical epidemiology in the same place and
year, and it served as a comparison parameter for the
other three tools. This method classifies trials as A, B
or C, according to whether there is a low, moderate or
high chance of bias in the primary studies, respec-
tively. This classification is mainly based on the in-
ternal validity of the study, its randomization method
and how it bypassed or minimized the bias. Thus, it
differs from the other assessment tools in that it is a
scrutinizing tool rather than a structured tool.17
The Delphi system is so called because the 206
items associated with study quality that were initially
listed were reduced to nine by means of the Delphi
consensus technique. It seeks to assess three dimen-
sions of the quality of studies: internal validity, ex-
ternal validity and statistical analysis.19
gestions coming from such reviews were subject to
bias and errors from various sources. In extreme cases,
this model for medical practice led to loss of effective-
ness and efficiency within the healthcare services.18
In attempts to weigh up the problem of the quality
of the information in relation to the pathways adopted,
the application of the epidemiological method to
clinical practice has shown the greatest consistency.
This method is known as clinical epidemiology.6
Within this methodological approach, the strongest
evidence for a given prophylactic or therapeutic in-
tervention is derived from studies in which several
randomized controlled clinical trials are developed
with a focus on the same treatment for the same con-
dition. This no longer follows the precepts of a narra-
tive review, but rather those of a systematic review.18
Such reviews form a modern method for evaluating
a set of simultaneous data,1 through making a sum-
mary of the medical literature (primary research). They
make use of explicit and reproducible methods for sys-
tematically searching for, critically analyzing and pro-
ducing syntheses of individual studies in what can
now be called a systematic review (secondary research).4
With regard to therapeutic intervention, evidence
level 1a, i.e. the best evidence that exists in relation
to a given therapeutic effect, comes from systematic
reviews of randomized controlled studies that may or
may not be accompanied by a statistical synthesis
called meta-analysis.1
Naturally, the quality of individual studies has ob-
vious relevance to systematic reviews and has an in-
fluence on the magnitude of the results. If the quality
of the primary material is inadequate, this may falsify
the conclusions of the review.11
Clinical studies may become corrupted acciden-
tally or deliberately, in various ways: in the randomi-
zation process, in the masking to the allocated treat-
ment, in the random generation of number sequences,
in the analysis, or even when the double-blind type
of masking is not implemented.
The need for analysis of the quality of these studies
has become obvious. Differences in quality ranking,
resulting from the use of different lists of criteria, may
cause serious problems in conducting systematic re-
views. Thus, empirical evidence is needed for estab-
lishing whether the quality assessment methods are
valid and reproducible.20
The objective of the present study was to compare
the results obtained from applying different quality
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The Jadad system consists of three topics that are
directly related to reducing bias (centered on the in-
ternal validity). All the questions have yes/no choices.
There are five points possible for its quality score:
three single points for yes responses and two addi-
tional points for appropriate methods of randomiza-
tion and ensuring blindness of allocation.9
The Maastricht system consists of 15 main items
based on methodological criteria for quality assess-
ment. These are divided into 47 subitems totaling
100 points, and these evaluate three dimensions of
the quality of a clinical trial: internal validity, exter-
nal validity and statistical method. The list gives four
response choices and weighting is given to the items
that reflect relative importance.20
It was decided to use these three methods because
they are tools that provide different types of assess-
ment, with very different numbers of items, scoring
systems with and without weighting, and sometimes
apparently complementary assessments. Thus, it was
sought to include assessment of the greatest possible
number of characteristics within the methodologies
of the clinical trials.
The quality scores for each system were calculated
in accordance with their original weighted values
(Jadad and Maastricht). For the Delphi list, equal
weighting was used for each item.
To make comparisons between the different sys-
tems, the quality scores obtained were transformed
into percentages, in relation to the maximum score
for each system. The percentages obtained for each
system were categorized into five classes: from 0 to
20% =1; from 21 to 40% =2; from 41 to 60% =3; from
61 to 80% =4; and from 81 to 100% =5.
The Spearman correlation coefficient was calcu-
lated between the quality percentages obtained by
the reviewers.
The Kappa test was performed to evaluate the con-
cordance between the reviewers regarding their clas-
sifications of the studies into categories, when the
utilized the different methods. Subsequently, consen-
sus meetings were held to reach definitive scoring
for each randomized controlled clinical trial.
After obtaining consensual scores, the studies were
ranked in decreasing order in terms of quality, taking
the ranking obtained after applying the Maastricht
system as the reference.
The weighted Kappa test was utilized for compar-
ing the quality rankings defined by applying each of
the evaluation systems.
To analyze the effect of intervention versus non-
intervention, it was determined that the studies that
obtained scores of greater than or equal to 50% of the
possible score using each tool, for at least two of the
quality tools utilized, would be considered to be the
best ones. For the clinical epidemiologists, the best
studies were the ones classified as A or B.
The statistical package Review Manager 4.1 was
utilized for performing the meta-analysis. Since only
dichotomous variables were utilized, the relative risks
were calculated with a 95% confidence interval.
To assess the estimated magnitude and/or direction
of effect resulting from the use of alpha interferon for
treating chronic hepatitis B, studies that reported the
primary outcomes of clearance of the hepatitis B virus
DNA (HBV-DNA) and/or the antigen “e” of the hepati-
tis B virus (HBeAg) within six months of ending the
treatment were included in the meta-analysis.
Given the heterogeneity identified among the clini-
cal trials included, the random effect model was uti-
lized for performing the meta-analysis.
RESULTS
Among the tools utilized, Delphi and Jadad were
considered easy to apply. The Maastricht method pre-
sented greater problems and required adaptations.
Because the Cochrane Collaboration method is un-
structured, it depends on previous familiarity with
the methods of clinical epidemiology.
Out of the 38 trials selected, only six (15.7%) were
published more recently than 1996, the year in which
CONSORT3 was published: a consensus that sought to
regulate the undertaking and publication of clinical
trials. All these trials were defined as randomized and
had in fact undergone some randomization method.
Twelve of them (31.5%) gave descriptions of the se-
quences and methodologies utilized. Only one of the
articles, by Tchrveniakova/Radev in 1999, described
the use of placebo control (multivitamin), although
without describing whether or not the placebo was
utilized in a way that was analogous to the treatment.
Only seven of the articles (18.4%) provided a re-
port of how the sample size was calculated.
In 22 of the articles (57.8%), losses and withdraw-
als from the trial and their causes were identified.
Detailed analysis of many trials that did not report
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the occurrence of losses found that such losses did in
fact occur and sometimes reached a proportion of more
than 10%, thereby introducing a potentially signifi-
cant bias in the conclusions from these trials.
In 23 of the articles (60.5%), the analysis took into
account the “intention to treat”, i.e. it took into con-
sideration all the patients that actually began the tri-
als in the intervention or control group, and not just
those who completed the study period.
In 27 of the articles (71%), the losses reported were
less than or equal to 10% of the randomized patients,
a quantity that is generally considered acceptable for
avoiding erroneous conclusions.
Table 1 presents quality scores for the tools uti-
lized, in decreasing order after reaching a consensus
between the reviewers.
Table 2 shows the concordance coefficient (Kappa)
relating to the application of the tools.
The Spearman correlation coefficient between the
tools showed that the correlation obtained between
the Maastricht and Jadad methods was 0.52
(p<0.0005), between Maastricht and Delphi was 0.53
(p<0.0007), and between Delphi and Jadad was 0.51
(p=0.0001). Even though these were only moderate
correlations, they were very homogeneous and much
greater that would be expected just by chance, and
thus statistically significant.
Comparison of the trial quality rankings obtained
through applying structured systems gave combined
concordance of 0.16, using the weighted Kappa test.
This was considered to be statistically significant
(p=0.02).
Figure 1 shows the meta-analysis of the effect of
intervention versus non-intervention, in relation to
the outcome of clearance of HBV-DNA, including all
the studies, regardless of quality assessment. Figure
2 presents the grouped analysis with the inclusion
only of the best-quality trials. The relative risk (RR)
and 95% confidence interval (95% CI) when only
Table 1 - Quality ranking of the trials on the treatment of chronic hepatitis B using alpha interferon, after reaching a consensus,
laid out in decreasing order.
N Author* Year Maastricht Delphi Jadad CE
(rank) (rank) (rank) (rank)
1 Sokal / Conjeevaran 1998 64 ( 1) 5 ( 1) 3 ( 1) A (1)
2 Jansen / Gerken 1999 62 ( 2) 4 ( 2) 3 ( 1) A (1)
3 Brook / Macdonald 1989 60 ( 3) 3 ( 3) 3 ( 1) A (1)
4 Fattovich / Farci 1992 58 ( 4) 4 ( 2) 3 ( 2) B (2)
5 Porres / Carreño 1988 57 ( 5) 4 ( 2) 2 ( 2) B (2)
6 Di-Biscegli / Fong 1993 56 ( 6) 4 ( 2) 3 ( 2) B (2)
7 Hoofnagle / Peters 1988 56 ( 6) 4 ( 2) 3 ( 2) B (2)
8 Sarin / Guptan 1996 56 ( 6) 4 ( 2) 3 ( 1) A (1)
9 Lok / Wu 1988 55 ( 7) 4 ( 2) 3 ( 3) C (3)
10 Pastore / Santantonio 1988 55 ( 7) 4 ( 2) 2 ( 2) B (2)
11 Saracco / Mazzela 1989 55 ( 7) 4 ( 2) 3 ( 2) B (2)
12 Carreño / Marcelin 1999 54 ( 8) 4 ( 2) 2 ( 2) B (2)
13 Muller / Baungarten 1990 54 ( 8) 3 ( 3) 2 ( 2) B (2)
14 Ruiz-Moreno / Rua 1991 54 ( 8) 3 ( 3) 2 ( 2) B (2)
15 Willian / Graig 1990 54 ( 8) 4 ( 2) 2 ( 3) C (3)
16 Fattovich / Brollo 1989 52 ( 9) 3 ( 3) 3 ( 1) A (1)
17 Ruiz-Moreno / Jimen 1990 52 ( 9) 3 ( 3) 3 ( 2) B (2)
18 Wong / Yim 1995 52 ( 9) 4 ( 2) 2 ( 1) A (1)
19 Carreño / Porres 1987 51 (10) 3 ( 3) 3 ( 2) B (2)
20 Carreño / Porres 1991 51 (10) 3 ( 3) 3 ( 3) B (2)
21 Pastore / Millella 1992 51 (10) 4 ( 2) 2 ( 2) B (2)
22 Realdi / Fattovich 1990 51 (10) 2 ( 4) 4 ( 2) B (2)
23 Alexander / Brahn 1986 50 (11) 3 ( 3) 3 ( 2) C (3)
24 Barbera / Bortolotti 1994 50 (11) 3 ( 3) 3 ( 2) A (1)
25 Brunetto / Olivieri 1989 50 (11) 3 ( 3) 3 ( 2) A (1)
26 Dusheiko / Paterson 1986 50 (11) 3 ( 3) 3 ( 1) C (3)
27 Perrilo / Schiff 1990 50 (11) 4 ( 2) 2 ( 1) A (1)
28 Brook / Chan / Yap 1989 48 (12) 5 ( 1) 1 ( 2) C (3)
29 Rumi / Romeu 1993 47 (13) 3 ( 3) 3 ( 2) B (2)
30 Tchrveniakova / Radev 1999 47 (13) 3 ( 3) 3 ( 3) C (3)
31 Utilli / Sagnelli 1991 45 (14) 2 ( 4) 4 ( 3) C (3)
32 Thomas / Lok 1994 44 (15) 4 ( 2) 2 ( 2) C (3)
33 Lampertico / Delninn 1997 43 (16) 4 ( 2) 2 ( 1) C (3)
34 Waked / Amin 1990 39 (17) 3 ( 3) 3 ( 2) C (3)
35 Hadzyianes / Bramou 1990 36 (18) 3 ( 3) 3 ( 2) C (3)
36 Mazzela / Villanova 1988 34 (19) 3 ( 3) 3 ( 2) C (3)
37 Lok / Lai 1986 32 (20) 2 ( 4) 4 ( 2) C (3)
38 Barbara / Mazzela 1986 30 (21) 2 ( 4) 4 ( 2) C (3)
Minimum / Maximum 30/ 64 2/ 5 1/ 3
Mean score (SD) 50.13 (7.7) 3.42 (0.75) 2.28 (0.61)
*The list of articles analyzed can be obtained upon request, from the first author of the present article
SD: standard deviation; CE: clinical epidemiologists
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the worst trials (n=25) were included were
RR=0.73 and 95% CI: 0.68-0.78.
The meta-analysis performed utilizing the
tool suggested by the Cochrane Collabora-
tion, on the trials that the infectologists con-
sidered to be in the A and B categories, found
RR=0.71 and 95% CI: 0.65-0.78, which was
little different from the previous findings.
Figure 3 presents the effect of the treat-
ment in relation to the clearance of HBeAg
with all the trials included in the meta-analy-
sis (n=23). When only the best ones were
included (n=11), RR=0.85 and 95% CI: 0.77-
0.93 were obtained, which thus only differed
in relation to the confidence interval.
DISCUSSION
The best articles were those that reported
on the randomization procedures, sample size
calculation, losses and their causes, and
analysis of intention to treat. They were es-
pecially the articles that very uniformly re-
ported losses of less than 10% of the total
number of randomized patients, thereby de-
creasing the chances of bias in the analysis
and erroneous conclusions.
Naturally, the worst trials had these characteristics
at much lower percentages, or did not present them.
Similar moderate statistically significant correla-
tions of between 0.51 and 0.53 were observed be-
tween the tools utilized for assessing the quality of
the studies. This was doubtlessly consequential to
the presence of a common core of items that sought
to analyze the internal validity of the studies. All
three of the lists contained items that verified the
randomization procedures and the presence/absence
of secrecy of allocation, for example.
In comparing the reproducibility of the applica-
tion of these tools between the reviewers, as meas-
ured using Kappa, statistical significance was not
reached for the Delphi system, even though the re-
producibility was greater than expected. In a way,
this was an unexpected result, since this is a system
that considers the assessment of the dimensions in-
volved in the quality of the clinical trials, and it is
easily understood and fast in its application. Three of
its items (the ones relating to the presence or absence
of placebo control) simply were not applicable, given
that only one of the studies incorporated in the re-
view included placebo control. This in itself would
have decreased the chance of discordance between
the reviewers.
The numbers show that, between the epidemiolo-
gists and the method adopted by them for evaluating
the quality of the studies, the concordance coeffi-
cient (Kappa) was moderate (0.53) and statistically
significant (p=0.0001).
The difference observed between the reviewers using
the quality assessment tools and the epidemiologists
using the method suggested by the Cochrane Collabo-
ration can be explained by the lower number of items
and practicality of the latter. Another explanation might
Table 2 - Concordance coefficient (Kappa) for the trials on the treatment of chronic hepatitis B using alpha interferon.
Method Observed Expected Kappa Standard p
concordance concordance deviation
Delphi 52.63 45.98 0.12 0.12 0.15
Jadad 55.26 36.91 0.29 0.10 0.002
Maastricht 78.95 68.35 0.33 0.12 0.004
Cochrane 68.42 31.72 0.53 0.10 0.0001
Figure 1 - Clearance of HBV-DNA at the end of the treatment using
alpha interferon, including all the trials (N=38).
Comparison: 01 Alpha-interferon versus no intervention or placebo
Outcome:        01 Persistence of serum HBV-DNA at end of treatment
Treatment RR
Study n/N n/N (95% CI Random)
WeightRR
(95% CI Random)%
Favours treatment Favours control
.1 .2 1 5 10
Control
3.8
0.1
3.5
1.7
3.9
1.7
3.0
2.3
3.7
2.5
2.8
2.1
1.6
2.9
3.3
4.6
3.5
1.8
1.8
0.8
3.3
1.2
4.3
5.0
1.6
3.7
1.5
1.8
2.8
0.9
1.9
5.3
2.3
4.6
1.9
0.4
2.3
3.5
100.0
17 / 23
1 / 9
26 / 40
12 / 45
25 / 37
7 / 12
8 / 10
12 / 16
20 / 27
14 / 25
10 / 14
11 / 17
11 / 30
15 / 25
21 / 31
44 / 61
15 / 21
16 / 34
16 / 34
7 / 33
19 / 28
 6/ 14
9 / 10
60 / 62
11 / 17
26 / 39
8 / 12
12 / 24
 19 / 31
7 / 33
10 / 20
57 / 70
18 / 31
94 / 179
7 / 10
3 / 16
17 / 23
19 / 25
710 / 1208
23 / 23
7 / 9
31 / 37
15 / 15
29 / 30
12 / 12
10 / 10
7 / 8
27 / 30
21 / 22
5 / 5
13 / 16
24 / 30
25 / 25
13 / 14
50 / 57
21 / 21
13 / 18
13 / 18
16 / 33
24 / 27
13 / 14
8 / 8
40 / 43
5 / 6
35 / 40
9 / 12
10 / 12
21 / 25
16 / 31
20 / 21
66 / 74
10 / 12
45 / 54
9 / 10
10 / 15
6 / 7
22 / 25
744 / 869
Alexander 1987
Barbera 1986
Barbera 1994
Brook 1989a
Brook 1989b
Brunetto 1989
Carreño 1987
Carreño 1991
Carreño 1999
Di Bisceglie 1993
Dusheiko 1986
Fattovich 1989
Fattovich 1992
Hadziyannis 1990
Hoofnagle 1988
Janssen 1999
Lampertico 1997
Lok 1986
Lok 1988
Mazzella 1988
Müller 1990
Pastore 1988
Pastore 1992
Perrilo 1990
Porres 1988
Realdi 1990
Ruiz Moreno 1990
Ruiz Moreno 1991
Rumi 1993
Saracco 1989
Sarin 1996
Sokal 1998
Tcherveniakova 1999
Tomas 1994
Utili 1991
Waked 1990
Willians 1990
Wong 1995
Total (95% CI)
Test for heterogeneity chi-square=71.34  df=37  0=0.00006
Test for overall effect  z=-8.98  p<0.00001
0.74[0.58,0.94]
0.14[0.02,0.94]
0.78[0.59,1.01]
0.27[0.16,0.43]
0.70[0.55,0,88]
0.58[0.36,0.94]
0.80[0.59,1.09]
0.86[0.58,1.26]
0.82[0.64,1.06]
0.59[0.41,0.84]
0.71[0.51,0.99]
0.80[0.52,1.22]
0.46[0.28,0.76]
0.60[0.44,0.83]
0.73[0.55,0.97]
0.82[0.68,0.99]
0.71[0.54,0.94]
0.65[0.41,1.03]
0.65[0.41,1.03]
0.44[0.21,0.92]
0.76[0.57,1.02]
0.46[0.25,0.86]
0.90[0.73,1.11]
0.79[0.67,0.92]
0.78[0.47,1.28]
0.76[0.59,0.98]
0.89[0.53,1.49]
0.60[0.37,0.96]
0.73[0.53,1.01]
0.41[0.20,0.86]
0.52[0.34,0.82]
0.91[0.80,1.05]
0.70[0.47,1.03]
0.63[0.52,0.76]
0.78[0.49,1.23]
0.28[0.10,0.83]
0.86[0.59,1.27]
0.86[0.66,1.12]
0.71[0.66,0.77]
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that, in the latter, the score assessment is given on the
basis of whether a characteristic was reported (how the
patients were allocated, for example), rather than whether
this was done adequately in the study.17
The present study has shown that, depending on
the type of scale utilized for evaluating the
quality of the publications, different quality
ranks will be defined among the studies in-
corporated into the systematic review. This
has already been observed by other investi-
gators.10
The statistically significant result from the
weighted Kappa test (p=0.02) allows the con-
clusion that, despite the low concordance
obtained (Kappa=0.16), the quality ranking
for the studies was similar.
When all the studies were included and
the effect on the clearance of the HBV-DNA
was measured, the value obtained was
RR=0.71; 95% CI: 0.66-0.77. When only the
studies considered to be the best ones were
included, the value obtained was RR=0.67;
95% CI: 0.58-0.79, and thus a difference in
risk of 33%. When only the studies that did
not reach the quality threshold were tested,
the RR was 0.73 (95% CI: 0.68-0.76), which
was very close to the preceding values and
in the direction of lower effect from the inter-
vention (27%).
The literature regularly indicates an over-
estimate of the effect when lesser studies are
introduced into the meta-analysis, because
these are usually developed with lower meth-
odological rigor.4
The same would occur if studies with lower
quality scores were to be introduced.12 On the
other hand, when it was sought to compare
the effect of the treatment between the low
and high-quality studies, no correlation was
found between the quality measurement and
the magnitude of the effect of the treatment,
and in particular in relation to the variables of
utilization of double-blind procedure and se-
crecy of allocation. However, the possibility
that certain quality measurements might be
associated with the effect of the treatment can-
not be discarded, with regard to clinical situa-
tions or questions of specific interest.2
The result from the meta-analysis utiliz-
ing the best articles (A+B) defined by the
epidemiologists while measuring the same
outcome (RR=0.72; 95% CI: 0.64-0.80) was very simi-
lar to what was obtained by means of scrutiny using
the other three quality assessment tools. This rein-
forces the efficacy of the method proposed by the
Cochrane Collaboration for assessing the quality of
clinical studies.
Figure 2 - Clearance of HBV-DNA at the end of the treatment using
alpha interferon, including the trials that obtained scores of ≥50% from
the quality assessment tools (N=13).
Compparison: 01 Alpha-interferon versus no intervention or placebo
Outcome:        01 Persistence of serum HBV-DNA at end of treatment
Treatment RR
Study n/N n/N (95% CI Random)
WeightRR
(95% CI Random)%
Control
0.27[0.16,0.43]
0.59[0.41,0.84]
0.71[0.51,0.99]
0.80[0.52,1.22]
0.46[0.28,0.76]
0.73[0.55,0.97]
0.82[0.68,0.99]
0.65[0.41,1.03]
0.79[0.67,0.92]
0.41[0.20,0.86]
0.53[0.34,0.82]
0.91[0.80,1.05]
0.86[0.66,1.12]
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Figure 3 - Clearance of HBeAg at the end of the treatment using alpha
interferon, including all the studies that assessed this outcome (N=23).
Comparison: 01 Alpha-interferon versus no Intervention or placebo
Outcome:        04 Persistence of serum HBeAg at end of treatment
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From analysis of the magnitude of the effect in rela-
tion to the second outcome examined (clearance of
HBeAg), the results were found to differ only in relation
to the confidence interval. The magnitude of the effect
measured was smaller than for the previous outcome.
All the articles analyzed determined an outcome
favoring intervention. Thus, comparison of the best
versus the worst did not alter the direction of the ef-
fect, which was maintained with different magnitudes
but always in favor of intervention.
A hypothesis can be put forward that, in perform-
ing a systematic review and meta-analysis using stud-
ies that are discordant in relation to the direction of
the effect, there will be greater likelihood of observ-
ing variation in the effect of the intervention, de-
pending on the quality of the studies included.
The inclusion of articles of both good and bad
quality in the systematic reviews may increase their
heterogeneity (the extent to which the results from
“similar” randomized controlled clinical trials di-
verge from each other). This may not necessarily be
a bad thing, given that heterogeneity is a reality in
clinical practice.
This point has been raised previously, with emphasis
on the fact that if all randomized controlled clinical
trials were filled with patients of uniform age, sex, loca-
tion and therapeutic intervention, the estimates from
grouped analyses ought to be very precise, but their
conclusions would only apply to similar groups and
locations. Their external validity would be reduced.16
In developing secondary studies, such as system-
atic reviews, and assessing the quality of primary stud-
ies, certain characteristics that produce consequences
for modern reviews must be taken into account. One
of these is that the results from older clinical trials
may be less reliable, since they were conducted at a
time when the methodology was less rigorous and
reproducible. Therefore, they may not be comparable
with more modern studies, with regard to outcomes
and how to measure them, for example.7
On the other hand, among studies that offer an in-
adequate description of the tests performed or the
population studied, even if it is plausible to believe
that this shows design deficiencies and hides bias, it
is not always what has in fact occurred. It is often
impossible to distinguish between poor design qual-
ity and research conduct and poor quality of the de-
scription. This latter may have occurred, for example,
because of the meager space available for publica-
tion in top journals.4
The procedures required for performing such trials
demonstrate that it is not simply the quality assess-
ment for the randomized controlled clinical trials that
should be included in a systematic review and meta-
analysis. Unless a consensus for defining the quality
measurement is robustly constructed and validated,
the concordance when applying it may be found to
be unacceptably low.
It should be considered that trained epidemiolo-
gists making use of simpler methodology from the
Cochrane Collaboration, for classifying the quality
of the primary studies, arrived at practically the same
result.
It is clear that, until there is a consensus regarding
the development and publication of randomized and
controlled clinical trials that is adopted without re-
striction,3 and also regarding how to report them, as-
sessments of their methodological quality must be
considered to be a routine procedure when perform-
ing systematic reviews and meta-analyses.14
Assessment of the quality of randomized clinical
trials offers an estimate of the likelihood that their
results will express the truth. This does not rule out
the need to perform procedures for meticulous indi-
vidual evaluation, especially in relation to the gen-
eration of randomization and conducting of alloca-
tion procedures for the intervention, the secrecy of
the distribution and assessment of the effect of the
intervention, and also the degree of adherence to
the treatment and how losses are handled in the
analysis.
Researchers of little ethical commitment or who
lack capability, and even those in the pharmaceuti-
cal industry, may cause their randomized control-
led clinical trials to reach the maximum scores pos-
sible by utilizing a wide variety of quality scales.
They may in this way defraud premises, objectives,
analyses and the most appropriate moment for dis-
seminating the information necessary for good clini-
cal practice.8
Perhaps the best way of overcoming the problem
will be through increasingly explicit statement of po-
tential conflicts of interest in the development and
publication of studies. It will furthermore come from
progressive public support for well-trained research-
ers who do not have links to objectives other than
seeking the wellbeing of the majority of the popula-
tion, and who patiently develop detailed and dis-
cerning analysis of the design and conduct of clini-
cal trials, in order to build and strengthen Evidence-
Based Medicine.
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